Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Omeros Logo
Omeros Growth Score
75
CB Rank
24732
Heat Score
64
Omeros is a clinical-stage biopharmaceutical company developing products focused on inflammation and central nervous system disorders.
Founded
obfuscation
PublicPost-IPO Equity Seattle, Washington, United States101-250 www.omeros.com
Biotechnology
Health Care
Pharmaceutical
Overview

Omeros
Total Funding
obfuscation
Growth Score
75
Heat Score
64

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score75
-15 pts
in past quarter
Heat Score 64
-9 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Omeros

CB Rank
24732
Omeros is a clinical-stage biopharmaceutical company developing products focused on inflammation and central nervous system disorders.
Founded
obfuscation
PublicPost-IPO Equity Seattle, Washington, United States101-250 www.omeros.com
Biotechnology
Health Care
Pharmaceutical

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Debt
OBF
in
obfuscation
Grant
OBF
in
obfuscation

Key People

Details

Legal Name Omeros Corporation
Operating Status Active
Stock Symbol  NASDAQ:OMER
Company Type For Profit
Founders  Gregory Demopulos, Pamela Pierce Palmer
About the Company
Omeros is a Seattle-based commercial-stage biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system.
Phone Number 2066765005
Diversity Spotlight 
Women Founded
Predictions & Insights

Growth Insight

See this Growth Insight
Omeros is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

Narsoplimab (OMS721)
A monoclonal antibody targeting MASP-2 to inhibit the lectin pathway of the complement system, used to treat complement-mediated diseases like stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
OMS906 (Zaltenibart)
A humanized monoclonal antibody targeting MASP-3 to inhibit the alternative pathway of the complement system, under development for diseases like paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy.

Research & Development

Omeros is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 26
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Omeros Logo
Post-IPO Equity - Omeros
1
obfuscation
Polar Asset Management PartnersPost-IPO Equity
obfuscation
Post-IPO Equity - Omeros Logo
Post-IPO Equity - Omeros
1
obfuscation
Polar Asset Management PartnersPost-IPO Equity
obfuscation
Post-IPO Equity - Omeros Logo
Post-IPO Equity - Omeros
1
obfuscation
Polar Asset Management PartnersPost-IPO Equity
obfuscation
Post-IPO Equity - Omeros Logo
Post-IPO Equity - Omeros
1
obfuscation
Polar Asset Management PartnersPost-IPO Equity
obfuscation
Post-IPO Equity - Omeros Logo
Post-IPO Equity - Omeros
1
obfuscation
Polar Asset Management PartnersPost-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 26
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Omeros Logo
Post-IPO Equity - Omeros
1
obfuscation
Polar Asset Management PartnersPost-IPO Equity
obfuscation
Post-IPO Equity - Omeros Logo
Post-IPO Equity - Omeros
1
obfuscation
Polar Asset Management PartnersPost-IPO Equity
obfuscation
Post-IPO Equity - Omeros Logo
Post-IPO Equity - Omeros
1
obfuscation
Polar Asset Management PartnersPost-IPO Equity
obfuscation
Post-IPO Equity - Omeros Logo
Post-IPO Equity - Omeros
1
obfuscation
Polar Asset Management PartnersPost-IPO Equity
obfuscation
Post-IPO Equity - Omeros Logo
Post-IPO Equity - Omeros
1
obfuscation
Polar Asset Management PartnersPost-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Polar Asset Management Partners Logo
Polar Asset Management Partners
Yes
Post-IPO Equity - Omeros Logo
Post-IPO Equity - Omeros
—
Polar Asset Management Partners Logo
Polar Asset Management Partners
Yes
Post-IPO Equity - Omeros Logo
Post-IPO Equity - Omeros
—
Polar Asset Management Partners Logo
Polar Asset Management Partners
Yes
Post-IPO Equity - Omeros Logo
Post-IPO Equity - Omeros
—
Polar Asset Management Partners Logo
Polar Asset Management Partners
Yes
Post-IPO Equity - Omeros Logo
Post-IPO Equity - Omeros
—
Polar Asset Management Partners Logo
Polar Asset Management Partners
Yes
Post-IPO Equity - Omeros Logo
Post-IPO Equity - Omeros
—

Investments

Number of Acquisitions 1

Investment Breakdown

Number of Acquisitions 1
Market Intelligence
People
View Profiles & Contacts
Headcount 101-250 Employee Profiles 8 Board Members and Advisors 1 Contacts 221

Employee Profiles

Board Members and Advisors

News

News and Press

News•Jul 6, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jul 6, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jul 2, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jul 1, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

4,339
-9.98%
 in past month

Interest Signals

TopicSurge Score
Food / Cafeteria Plans Logo
Food / Cafeteria Plans
100
FinTech Logo
FinTech
100
Reorganization Logo
Reorganization
100

Actively Used Products

28Omeros uses 28 technology products and services including HTML5, Lightbox, and  Wordpress, according to G2 Stack.

Active Website Tech Count

13Omeros is actively using 13 technologies for its website, according to BuiltWith. These include IIS 10, IIS, and  Express.

Total IP

212The intellectual property of Omeros includes 170 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery. Additionally, Omeros has registered 42 trademarks with the most popular class being 'Pharmaceutical, veterinary and sanitary products', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Omeros's headquarters? Omeros is located in Seattle, Washington, United States.Who invested in Omeros? Omeros has 20 investors including Polar Asset Management Partners and  National Institute on Drug Abuse (NIDA).When was the last funding round for Omeros? Omeros closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are Omeros's competitors? Alternatives and possible competitors to Omeros may include Alto Neuroscience, Canton Strategic Holdings, and  ImageneBio.How much funding has Omeros raised to date? Omeros has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(5d42803 1)
|